Skip to Content
Søk Menu

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

Interview: The effectiveness of avelumab is consistent with the results of the JAVELIN Bladder 100 study.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Highlights From the Nordic Urothelial Cancer Oncology Group (NUCOG)

/ Katrine Ørum / Helle Pappot / Anders Ullén
Blærekreft

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrekreft
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærekreft Play the Video 08:59

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatakreft

Efficacy of 1L Treatment Does Not Predict Efficacy of 2L Cabozantinib for Patients with mRCC

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrekreft
Philippe Barthélémy

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

/ Philippe Barthelemy
ASCOGU25 Play the Video 03:28

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Nyrekreft
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25BlærekreftType 2-diabetes Play the Video 02:42
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Blærekreft Play the Video 06:12
Back to top